Exercise period for warrants of series TO4 and TO5 in CombiGene AB (publ) begins today
Today, the exercise period for subscription of shares in CombiGene AB (publ) (“CombiGene” or the “Company”) begins on the basis of warrants of series TO4 and TO5. Each warrant of series TO4 and TO5 entitles to subscription for one new share in CombiGene from and including
16 November 2020 up to and including 30 November 2020 at a subscription price of SEK 0.5, because the subscription price per share could not be lower than SEK 0.5.
On February 18, 2020, CombiGene issued inter alia 26,284,180 warrants of series TO4 in the Company’s rights issue. On April 24, 2020 CombiGene issued inter alia an additional 4,000,000 warrants of series TO4 in a private placement to Modelio Equity AB (publ) and Oscar Molse. Thereafter, on 4 August 2020, CombiGene issued inter alia 21,588,125 warrants of series TO5 in a private placement to NYIP. Warrants of series TO5 have the same terms as warrants of series TO4 but are not listed.
CombiGene has in total issued 51,872,305 warrants of series TO4 and TO5. In the case of full subscription at the subscription price of SEK 0.5, CombiGene will be granted SEK 25,936,152.5 before issue costs, with the total number of shares increasing by 51,872,305 shares to 230,094,481 shares and the share capital increasing by SEK 5,187,230.5 to SEK 23,009,448.1, corresponding to a dilution effect of approximately 22.54 percent of CombiGene’s share capital and votes. Dilution effect refers to the number of newly issued shares and additional votes as a result of full exercise of the warrants of series TO4 and TO5 in relation to the total number of shares and votes in CombiGene after the new shares have been registered.
Please note that if the warrants of series TO4 are not exercised for subscription of shares by November 30, 2020 at the latest or disposed of by November 26, 2020 at the latest, they will expire and lose their value and will be cleared from the VP account or depositary.
The application form, the Board’s report and auditor’s statement as well as the full terms and conditions for the warrants of series TO4, a copy of CombiGene’s Articles of Association, a copy of the annual report containing the most recently adopted balance sheet and income statements, including the audit report for the financial year, are available at the Company and on the Company’s website, www.combigene.com.
Holders of warrants held in an account (Sw. depå), investment savings account (Sw. investeringssparkonto) or an endowment account (Sw. kapitalförsäkring), please contact your depository agent in order to exercise the warrants.
Holders of warrants held in a VP account should use the application form “Anmälningssedeln TO 4”. In connection with the application form being sent to Partner Fondkommission, payment shall be made according to the instructions on the application form.
The results of the exercise period will be announced in December 2020.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.